Promising new combo targets rare eye cancer in early trial
NCT ID NCT07247383
First seen Dec 08, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tests a new drug (orelabrutinib) combined with either low-dose radiation or another drug (rituximab) for a rare type of eye lymphoma called ocular adnexal MALT lymphoma. The goal is to see how well the treatment shrinks or eliminates the cancer. The trial includes 39 adults with early-stage disease who have not had prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2ndAffiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.